


Syntázy oxidu dusnatého (NO synthases - NOSs)

Oxid dusnatý (NO)

- Zloženie: atóm kyslíku a dusíku viazané dvojnou väzbou
- Atom kyslíku nesie 2 páry (nevazebných) elektónov
- Atom dusíku má 1 pár nevazebných elektrónov a jeden nepárový elektrón





Robert F Furchtgott
1916
Dept. of Pharmacology,
SUNY Health Science Center
New York




Louis J Ignarro,
1941
Dept. of Molecular and
Medical Pharmacology
UCLA School of
Medicine
Los Angeles



Ferid Murad
1936
Dept. of Integrative Biology
Pharmacology and
Physiology
University of Texas Medical
School, Houston




- V savčích buňkách je NO tvořen oxidací terminálного guanidino dusíku L-argininu molekulárním kyslíkem; kromě NO vzniká L-citrulin.
- Celou komplexní reakci katalyzuje jediný enzym, NO syntáza, která existuje 3 isoformách.



Ignarrova spektrální analýza
Ignarro pomocí spektrální analýzy prokázal, že EDRF je totožný s NO.


Hemoglobin (žlutý) exponovaný endoteliálním buňkám produkujícím EDRF (konverze oxyhemoglobinu na methemoglobin).

Hemoglobin (žlutý) exponovaný přímo NO. Posun v absorbční krivce je identický (EDRF = NO).



Furchtgottův sandwich

Furchtgott prokázal, že relaxace cév indukovaná acetylcholinem je závislá na endoteliu. Použil dva kousky aorty, u jednoho odstranil epitelium



Muradova enzymatická aktivace

Murad věděl, že nitroglycerin působí relaxaci hladké svaloviny. Enzym guanylát cyklosa byla aktivována a indukovala zvýšení cGMP s následnou relaxací svalu. Působí nitroglycerin cestou uvolňování NO ??? Probublával NO přes tkáň obsahující enzym – cGMP se zvyšoval.

Něco málo chemie o NO

- NO je radikál (lichý počet valenčních elektronů, konkrétně 11 - o 1 více než N₂, o 1 méně než O₂)
- to, že je to radikál, se někdy zdůrazňuje tečkou (NO), to ale není nutné, "radikálovost" je implicitní v označení NO
- z N₂ a O₂ se tvoří jen za specifických podmínek při vysokých teplotách, např. při blesku: taky vzniká ve spalovacích motorech a tepelných elektrárnách
- samovolně se nerozkládá, jen za vyššího tlaku - při něm pozvolna vzniká 2-3 % toxickeho NO₂ za měsíc (pozor na skladování v bombách!)
- poměrně málo rozpustný ve vodě (~1.7 mmol/l při 25°C), t.j. řádově podobně jako O₂ či N₂
- v přítomnosti kyslíku podléhá autooxidaci za vzniku NO₂: $2 \text{NO} + \text{O}_2 \rightarrow 2 \text{NO}_2$
- autooxidace je asi 200x rychlejší v roztoku než v plynné fázi
- autooxidace je rychlá (několik sec), je-li NO i O₂ hodně, ale celkem pomalá, je-li NO málo - jako je tomu většinou v tkáních, kde je NO méně než 10 μM (poločas NO tam může být až 500 sec)
- ve vodném roztoku jsou produktem autooxidace nitryty (NO₂⁻), pouze v přítomnosti hemoproteinů proběhne oxidace až na nitráty (NO₃⁻)
- v přítomnosti superoxidu vzniká extrémně rychle peroxynitrit:
 $\text{NO} + \text{O}_2^- \rightarrow \cdot\text{OONO}$
·OONO není radikál, ale je velmi reaktivní a cytotoxický
- NO je velmi rychle inaktivován oxidací s železem **oxyhemoglobinu** za vzniku NO₃⁻


FYZIOLOGIE NO

- Neurotransmitter - učení, paměť, spánek, bolest, deprese
- Zabijí viry, baktérie, parazity, tumory (iNOS; indukci inhibují kortikosteroidy)
- Inhibuje mitochondriální respiraci
- Vazodilatace závislá na endotelu (ACh, eNOS)
- Nejvíce NO se dělá v nose a paranasálních dutinách
 - Pravděpodobně důležité pro jejich dezinfekci
 - NO lze dobře měřit ve vydechovaném vzduchu
 - Malá část vydechovaného NO pochází z dolních dýchacích cest (lze měřit odebíráním vzorků z úst) - mění se při některých nemocích, např. astma)


ÚČINKY NO NA CÍLOVOU TKÁŇ

- při velkých množstvích obvykle převládá oxidace (O₂, O₂⁻) za tvorby **reaktivních, cytotoxických produktů** (ONOO⁻) - zabíjení i jinak obtížně zlikvidovatelných baktérií (např. Mycobacterium tuberculosis), hub, parazitů a tumorů, inhibice replikace virů
- v nižších koncentracích je oxidace pomalá, většinou převládá regulační působení prostřednictvím aktivace solubilní isoformy enzymu guanylát cyklázy (heterodimer obsahující hem, s kterým právě NO interaguje)
- aktivace guanylát cyklázy zvyšuje v cílové buňce koncentraci cyklického guanosin-3',5'-monofosfátu (cGMP), ten zprostředkuje účinky NO

Atmospheric Nitrogen Oxides



NO sensitizuje presynaptický neuron k silnějšímu signálu. To následně vede k silnější odpovědi postsynaptického neuronu.



Příklad: koncentrace NO ve vydechovaném vzduchu zdravých lidí. Hodnoty jsou nejvyšší při odebírání vzorků z nosu a postupně nižší v ústech a distálnějších úsecích dýchacích cest. V periferní prùdušce je koncentrace NO pod detekčním limitem vysoko citlivé chemiluminiscenční metody (Chest 110: 930-938: 1995).

Syntázy oxidu dusnatého

- neuronální syntáza oxidu dusnatého (NOS1 = nNOS)
- inducibilní syntáza oxidu dusnatého (NOS2 = iNOS)
- endotheliální syntáza oxidu dusnatého (NOS3 = eNOS)

Každá z těchto syntáz:


- má rozdílnou tkáňovou distribuci
- lokализovaná na různých chromozomech

Všetky 3 isoformy NO syntázy

- Sú aktívne ako homodiméry
- Obsahujú v aktívnom centre hem
- Sú stereošpecifické (D-arginin nie je substrátom)
- Jako kofaktory vyžadujú:
 - NADPH
 - 6(R)-5,6,7,8-tetrahydrobiopterin (BH₄)
 - FAD FMN
 - kalmodulin (ten sa k NOS typu I a III váže po navázání Ca na kalmodulin, NOS II váže kalmodulin trvale)

Flavin adenine dinucleotide (FAD) is the precursor molecule to **FADH₂**. Upon binding to two hydrogen atoms, FAD is then changed to FADH₂ and is turned into an energy-carrying molecule. FAD is a coenzyme derived from **riboflavin**, or vitamin B₂. Many **oxidoreductases**, called **flavoenzymes** or **flavoproteins**, require FAD as a prosthetic group which functions in electron transfers.

Flavin mononucleotide (FMN), or **riboflavin-5'-phosphate**, is also derived from **riboflavin** (vitamin B₂) and serves as a **cofactor** of various **oxidoreductases** including **NADH dehydrogenase**.



Electrons (e^-) are donated by NADPH to the reductase domain of the enzyme and proceed via FAD and FMN redox carriers to the oxygenase domain. There they interact with the heme iron and BH₄ at the active site to catalyse the reaction of oxygen with L-Arginine, generating citrulline and NO as products. Electron flow through the reductase domain requires the presence of bound Ca²⁺/CaM.


Name	Present in	Stimuli	Description
Neuronal NOS (nNOS or NOS1)	Central and peripheral neurons, platelets, pancreatic β cells, epithelial cells	NMDA, insulin, thrombin	Produces NO in neuronal tissue in both the central and peripheral nervous system. Neuronal NOS also performs a role in cell communication and is associated with plasma membranes. nNOS action can be inhibited by NPA (N-propyl-L-arginine).
Inducible NOS (iNOS or NOS2)	Macrophages, endothelial cells, chondrocytes, hepatocytes, smooth muscle cells	Endotoxin, IFN- γ , IL-1, TNF- α	Can be found in the immune system but is also found in the cardiovascular system. It uses the oxidative stress of NO (a free radical) to be used by macrophages in immune defence against pathogens.
Endothelial NOS (eNOS or NOS3 or constitutive/ cNOS)	Endothelial cells, neurons, cardiac myocytes	Acetylcholine, ADP, thrombin, shear stress, VEGF	Generates NO in blood vessels and is involved with regulating vascular function. A constitutive Ca ²⁺ dependent NOS provides a basal release of NO. eNOS is associated with plasma membranes surrounding cells and the membranes of Golgi bodies within cells.

Za fyziologických podmienok sa oxid dusnatý tvorí v organizme v nízkych koncentráciách (pM). Je rozpustný vo vode a v lipidoch, a preto veľmi rýchlo a ochotne difunduje cez cytoplazmatické aj plazmatické membrány. V takomto prípade prevláda jeho regulačné pôsobenie:

cGMP-dependentné účinky – NO aktivuje enzym guanylát cyklázu, čím sa zvyšuje koncentrácia cyklického guanozin-3',5'-monofosfátu (cGMP) v cieťových bunkách. cGMP potom priamo reguluje mnohé bunkové funkcie. Riadi niektoré bunkové kanály, znižuje intracelulárnu koncentráciu Ca^{2+} iónov a inhibuje kontraktilný aparát v hladkom svalstve. Okrem toho reguluje väzodilatáciu ciev, moduluje srdcovú kontraktilitu a znižuje zrážanlivosť krvi. Nemenej doležitý je jeho funkčný podiel na neurotransmisii a tvorbe pamäťovej stopy.



cGMP-independentné účinky - V tomto prípade sa oxid dusnatý uplatňuje pri inhibícii syntézy DNA a aj celkového energetického metabolizmu bunky. Reguluje metabolismus železa.

Pri zápalových procesoch sa jeho koncentrácia v organizme mnohonásobne zvyšuje (μM). Vtedy sa NO a aj jeho reaktívne metabolity účastnia na protizápalových, antibakteriálnych, antivirálnych a antioxidačných procesoch. Cytotoxicke a cytostaticke účinky oxidu dusnatého sprostredkovávajú bunky imunitného systému, zúčastňujúce sa zápalových procesov. Sú to neutrofily, monocyty a makrofágy.



Neuronal Nitric Oxide Synthase (nNOS, Type I)

- Homodimers with 2 subunits (130-160 kDa)
- nNOS have binding sites for NADPH, FAD, and FMN near the carboxyl terminus (the reductase domain), and binding sites for tetrahydrobiopterin (BH₄) and heme near the amino terminus (the oxygenase domain). The reductase and oxygenase domains are linked by a calmodulin (CaM) binding site. Occupation of this site facilitates electron transfer from the cofactors in the reductase domain to heme during nitric oxide production.
- nNOS is associated with the post-synaptic density protein (PSD-95) in the neuronal membrane. In response to increased intracellular Ca²⁺, nNOS interacts with CaM. The Ca²⁺-CaM complex, in combination with BH₄, binds to nNOS and induces its translocation from the plasma membrane to the cytoplasm.
- The dephosphorylation of nNOS by calcineurin initiates the production NO. NO activates guanylyl cyclase (GC) and activates the various cGMP-regulated signaling pathways.
- nNOS is inactivated by phosphorylation by protein kinase A (PKA) or protein kinase C (PKC).
- Neuronal nitric oxide synthase (nNOS) has been implicated in a wide variety of physiological and pathological processes. These include neurotransmission, neurotoxicity, skeletal muscle contraction, sexual function, body fluid homeostasis and atherosclerosis, among others.



- NMDA receptor (NMDAR) is an ionotropic receptor for glutamate
- NMDA (N-methyl d-aspartate) is a name of its selective specific agonist
- Activation of NMDA receptors results in the opening of an ion channel that is nonselective to cations. This allows flow of Na⁺ and small amounts of Ca²⁺ ions into the cell and K⁺ out of the cell.
- Calcium flux through NMDARs is thought to play a critical role in synaptic plasticity, a cellular mechanism for learning and memory. The NMDA receptor is distinct in that it is both ligand-gated and voltage-dependent.
- Activation of NMDA receptors requires binding of glutamate or aspartate (aspartate does not stimulate the receptors as strongly). In addition, NMDARs also require the binding of the co-agonist glycine for the efficient opening of the ion channel, which is a part of this receptor.


Endothelial nitric oxide synthase (eNOS or NOS3 or constitutive/ cNOS)

- localised to caveolae
- eNOS is a lipid raft/caveolar protein apparently regulated by caveolin
- Agonist stimulation induces calcium dependent association of protein cofactors and kinases ultimately resulting in generation of nitric oxide from Arginine

Regulation of Endothelial Nitric Oxide Synthase

Classical regulation by calcium

- All NO-synthases required for its activation to be bound to a calcium regulatory protein: **calmodulin**.
- iNOS tightly binds calmodulin even at resting calcium concentrations, and then it is active once it is synthetized.
- Constitutive enzymes, eNOS and nNOS, only bind calmodulin when the intracellular calcium concentration increase up to a certain value. Agents that increase intracellular calcium concentration, either by allowing calcium entrance from the outside or by stimulating calcium mobilization from intracellular stores, can activate these constitutive enzymes.
- In endothelial cells various substances increase intracellular calcium and in consequence NO synthesis: **bradykinin, histamine, serotonin**.



Calcium-independent regulation

Activity of eNOS is acutely dependent on intracellular localization and also dependent on phosphorylation at specific aminoacids.

Intracellular localization


- eNOS is predominantly localized in caveolae (specialized invaginations of the plasma membrane), where it is closely regulated by interaction with caveolin-1. Modifications preventing membrane localization of eNOS also result in the absence of NO synthetic activity in the intact cells. Membrane distribution is probably needed by the presence in the same localization of other proteins important for eNOS activity: the cationic amino acid transporter CAT-1 (involved in the uptake of L-arginine, substrate for NO synthesis), calcium pump and the bradykinin receptor are also present in caveolae.
- Although membrane distribution is an essential requirement for eNOS activity, at plasma membrane the enzyme activity is closely regulated by caveolin-1. This intrinsic protein strongly reduces eNOS activity by interfering with calmodulin binding. Intracellular calcium increase or shear stress displace caveolin-1 and allow eNOS activation.
- Membrane localization of eNOS is modulated by certain post-translational modifications:
 - Myristylation distinguish eNOS from nNOS and iNOS, that are predominantly cytosolic proteins
 - Palmitoylation is also required for a proper localization of eNOS in the membrane

Phosphorylation: Tyr-Phosphorylation, Ser/Thr-Phosphorylation

Oxygen free radicals


- In addition to direct regulation of NO-synthases, NO availability is also dependent on the quantity of oxygen free radicals generated by cells surrounding NO-producer cell. In fact, eNOS may generate superoxide instead of NO in certain conditions (e.g. low L-arginine levels). Whatever the origin of superoxide (eNOS, xanthine oxidase,...) this compound rapidly reacts with NO to form peroxynitrite. In certain pathological circumstances an increase in superoxide formation can be determinant in reducing NO availability.

[Based on Govers and Rabelink, Am J Physiol 2001, 280:F193]



Regulation of eNOS

- factors that regulate the transcription of eNOS gene (shear stress, estrogen and hypoxia)
- factors that modulate the stability of its mRNA (tumor necrosis factor alfa or TNF-alfa, lipopolysaccharide or LPS, and vascular endothelial growth factor or VEGF)
- permanent changes of the eNOS protein e.g. myristoylation, palmitoylation, myristoylation seems a critical factor to allow the final location of the enzyme at certain specific domains of the membrane.
- non-permanent changes of eNOS protein e.g. phosphorylation and specific interactions with other proteins. After those modifications the eNOS protein is active and synthesizes NO or in some cases superoxide ion (this latter circumstance can take place when the substrate, L-arginine, or tetrahydrobiopterin are deficient and has pathophysiological consequences). Then, all these non-permanent modifications of eNOS revert and eNOS is deactivated. A cycle of activation-deactivation occurs in parallel with a cycle of association and dissociation from the caveole at the plasma membrane. [Based on Govers and Rabelink, Am J Physiol 2001, 280:F193]



Caveolae

- small invaginations (vesicles) of the plasma membrane with a well-defined size (50-100 nm) and a particular lipid content
- localised in plasma membrane (**lipid rafts**-rich in glycosphingolipids and cholesterol)
- Involved in transcytosis, lipid trafficking and more recently signal transduction
- very dynamic organelles that can pinch off the plasma membrane in a process that requires the hydrolysis of GTP
- mediate trans-epithelial transport of small molecules across the cell by fusing together to form trans-cellular channels
- mediate the uptake of particular molecules and ions from the exterior and then redistribute these compounds in intracellular compartment through a process called potocytosis
- cycle between the plasma membrane and the ER for delivery of molecules inside the cell
- many receptors and cytosolic signaling proteins that do not require lipid modifications to associate with membranes, such as PKC α , are reportedly found in caveolae
- number of viruses, parasites and bacteria utilize caveolae (or caveolae-like domains) as an alternative route to enter cells.

Proteins called caveolins


- represent major components of the caveolar coat
- important for the structure of caveolae, thanks to their ability to oligomerize and bind cholesterol
- caveolin-1 and 2 have a similar tissue distribution, being mainly expressed in endothelial, epithelial and muscle cells
- caveolin-3 expression is limited to muscle cells

caveolin-1 adaptor molecule or scaffolding protein in signal transduction Caveolin-1 functions as a tumor suppressor in human colon carcinoma cells


Bender et al., Biol Res 35 (2002) 139-150, Caveolae and caveolae-like membrane domains in cellular signalling and disease: Identification of downstream targets for the tumor suppressor protein caveolin-1

Lipid rafts

- In artificial membranes, different lipids separate from each other based on their physical properties, forming small islands called lipid rafts. These rafts have a higher concentration of certain specialized lipids, called glycosphingolipids and cholesterol than do non-raft parts of the membrane. Rafts are also distinguished by a different assortment of proteins. Certain types of proteins cluster together in rafts, while others remain mostly outside of rafts.
- Although the existence of lipid rafts in cellular membranes remains controversial, many scientists believe they serve as communication hubs by recruiting proteins that need to come together in order to transmit a signal. They are important signal transduction centers in the plasma membrane, coordinating and integrating incoming signals, especially in tyrosine kinase signalling. Researchers are beginning to link lipid rafts with a variety of diseases, including AIDS, Alzheimer's, anthrax, and atherosclerosis.



<http://www.scielo.cl/fbpe/img/bres/v35n2/img06-01.gif>




http://www.steve.gb.com/images/science/lipid_raft.png

Inducible nitric oxide synthase (iNOS, NOS II)

- generates NO independently of intracellular calcium concentrations
- induced by immunostimulatory cytokines, bacterial products or infection in a number of cells e.g. endothelium, hepatocytes, monocytes, mast cells, macrophages and smooth muscle cells (function in host defense against microbial and viral pathogens)
- responsible for formation of NO radicals or S-nitrosothiols or ONOO⁻ in the host cell or in the microbe itself
- participate in the pathology of inflammatory diseases including atherosclerosis, rheumatoid arthritis, diabetes, septic shock, transplant rejection, and multiple sclerosis, leading to cell death (F. Aktan, Life Sciences 75 (2004) 639–653)


Indukcia a regulácia iNOS expresie

- Indukcia iNOS:
 - nešpecifická (oxidatívny stres, UV-žiarenie)
 - Pomocou špecifických receptorov (ligandy TNF- α , IL-1, CD-40L, LPS)
- Regulácia iNOS sa uskutočňuje na **BUNEČNEJ** a **MOLEKULÁRNEJ** úrovni
- Kľúčovým faktor pre syntézu NO je zvýšenie expresie génu pre iNOS a regulácia transkripcie tohto génu (väzobné miesta pre transkripcné faktory, ktoré sa nachádzajú na iNOS promótore)
 - Miesta určené pre špecifické transkripcné faktory: jadrové faktory-kappaB (NF- κ B), aktivačný proteín-1 (AP-1), CCAAT/enhancer-binding protein C/EBP a cyklický-AMP-responzívny element viažúci proteín (CREB)
- Makrofágy (tkanivová forma monocytov) - veľmi dôležitú úlohu v zápalových procesoch (LPS, IFN- γ , TNF...). Odpoveď na stimuláciu → produkcia prozápalových mediátorov (IL-1, IL-2, TNF- α , NO...)



Regulation of iNOS induction at the molecular level.

Transcription factors controlling induction of the iNOS gene. Activated STAT1 induces transcription of the IRF-1 and iNOS genes, an effect which is competed by activated STAT6. IRF-1 interacts physically with NF- κ B, binds to the distal kB-binding site of the iNOS promoter region, and stimulates transcription. Only when NF- κ B is absent, IRF-2 can bind to the ISRE site and block transcription. Stimulatory pathways are indicated by green arrows (\rightarrow), and inhibitory pathways are drawn in red (Ellermann-Eriksen Virology Journal 2005).



Regulation of iNOS induction at the cellular level

Cytokines controlling the iNOS induction in macrophages during early HSV infection. IFN- γ , produced mainly by NK cells, stimulates iNOS production. This IFN- γ -induced production of iNOS can be inhibited by IL-4. Upon HSV (herpes simplex virus) infection of macrophages they produce TNF which synergizes with the IFN- γ -induced pathways and inhibits the inhibitory signals of IL-4. Thus, the virus overrules the restrictive signals and opens up for an otherwise closed pathway. Stimulatory pathways are indicated by green arrows (\rightarrow), and inhibitory pathways are drawn in red (Ellermann-Eriksen Virology Journal 2005).

Toll-like receptor



- transmembránové proteíny (monocyty, makrofágy, neutrofily, dendritické bunky, intestinálne epiteliálne a endoteliálne bunky)
- 13 členov (niektoré sú lokalizované intra- iné extracelulárne)
- Rozpoznávajú molekuly významné pre infekciu a zápal (LPS, Lipoproteíny, Fragmenty bakterálnych bičíkov, Bakteriálnu DNA, Dvojvláknovú (virálnu) DNA)
- Aktivácia:
 - Zahájenie rýchlych obranných reakcií
 - Dve signálne dráhy (NF- κ B transkripcné faktory, Mitogén-aktivované proteín kinázy (MAPK))
- Konečné produkty TLR-4 - cytokíny (IL-1 β , -6, -12, TNF) a RKM

LPS

- Súčasť bakteriálnej steny Gram-neg. baktérií
- endotoxín
- vyvoláva zápalové odpovede
- interaguje s LPS-viažúcim proteínom (LPS-BP) v sére a vytvára komplex ktorý sa v prítomnosti CD14 viaže na TLR-4
- Potrebná prítomnosť sekrečného proteínu MD-2

IFN- γ , IL-1, TNF receptor

- IFN- γ indukuje aktiváciu iNOS prostredníctvom Jak-STAT signálnej dráhy



NO pathways


Regulation and function of inducible nitric oxide synthase, arginase and related pathways in mouse macrophages. The activity of iNOS is regulated by cytokines and microbial products (such as LPS), which affect the uptake of L-arginine (L-Arg) by cationic amino acid transporters (CAT), the synthesis of cofactors, the expression of iNOS mRNA and protein, the enzymatic recycling of citrulline to arginine and the depletion of arginine by arginase. Polyamines- products of the arginase-ODC pathway, act as immunosuppressants and can further downregulate the production of NO. A high arginase activity in the absence of iNOS can also be associated with tissue fibrosis resulting from the increased synthesis of proline via the arginase-OAT pathway, which is required for collagen synthesis (for example, by fibroblasts). AL, argininosuccinate lyase; AS, argininosuccinate synthetase; MIF, macrophage migration inhibitory factor; ODC, ornithine decarboxylase; OAT, ornithine aminotransferase.

Regulácia iNOS sprostredkovaná MAP kinázami

- **ERK** (extracelulárnymi signálmi regulované kinázy).
- **p38 MAPK**
- **JNK** (c-Jun amino-terminálne kinázy)
- Sprostredkúvajú fosforyláciu ďalších proteínov (proteín kinázy, fosfolipázy, transkričné faktory a proteíny cytoskeletu)
- V bunkách majú rôzne funkcie
 - **ERK** regulujú bunkovú proliferáciu a diferenciáciu
 - **p38 MAPK a JNK** sprostredkovávajú apoptózu
 - **p38 MAPK a ERK** sú zapojené aj do regulácie expresie niektorých prozápalových génon (iNOS, IL-6)

Regulácia iNOS sprostredkovaná NF-κB

- štrukturálne a evolučne konzervovaná rodina proteínov pozostáva z piatich členov: NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA (p65), RelB a c-Rel
- Transkričné faktory **NF-κB** sa v nestimulovaných bunkách nachádzajú v inaktívnej forme (diméry) a nevyznačujú sa žiadnym účinkom na transkripciu príslušných génon
- Ich aktivácia je kontrolovaná inhibičnou podjednotkou zo skupiny inhibitorov kappaB (IκB)
- K aktivácii NF-κB dochádza pod vplyvom rôznych faktorov:
 - Nešpecificky
 - Špecificky pomocou ligandov TNF-α, IL-1, CD-40L a LPS → aktivujú transkričné faktory NF-κB prostredníctvom špecifických receptorov
 - aktivácia IκB kináz (IKK) (fosforylujú IκB zložku inaktívneho komplexu NFκB-IκB)
 - Uvoľnením inhibítora sa NF-κB stávajú aktívnymi a sú translokované do jadra
 - Vazba na svoj responzívny element a spustenie expresie cieľových génon
- NF-κB reguluje expresiu génon, ktoré hrajú veľmi dôležitú úlohu v nešpecifickej imuniti: cytokíny (IL-1, IL-2, IL-6, IL-12, TNF-α, Ltα, Ltβ a GM-CSF), adhezívne molekuly (ICAM, VCAM), proteíny akútnej fázy (SAA) a inducibilné enzýmy (iNOS a COX-2). Väzbou NF-κB na DNA dochádza zároveň k spätej indukcii transkripcie IκB. Inhibítor sa znova viaže na aktívne proteíny NF-κB.
- Aktivácia NF-κB je nevyhnutná pre LPS indukovanú expresiu iNOS, a používaním NF-κB inhibítarov dochádza k blokovaniu iNOS expresie a produkcie oxidu dusnatého v makrofágoch.



NOS inhibitor

Inhibitors of NOS have been described which interact with the NOS enzymes in a variety of ways:


- different sites (L-arginine, biopterin site, haem-binding inhibitors, flavoprotein and CaM inhibitors)
- differing time-dependence
- substrate-dependence
- mechanism of inhibition
- widely used inhibitors - L-NMMA, L-NNA and its methyl ester prodrug (*NG*-nitro-L-arginine methyl ester, 'L-NAME') - effect on nNOS dimerization but did inhibit both NOS and NADPH oxidase activity of nNOS, eNOS and iNOS in a time-dependent manner

Inhibitors of NOS

- widely used in experimental research
- still in under investigation for clinical application
- Treatment with NOS inhibitors (chronic inflammatory diseases, e.g. rheumatoid arthritis)
- Some such drugs are derivatives of arginine
- alkyl derivatives of isothiourea are very potent inhibitors of NOS
- Some experimental inhibitors that indeed do show some preference for iNOS and nNOS
- selective inhibition of iNOS should be advantageous in septic shock and in chronic inflammatory diseases

Sildenafil (Viagra)

- inhibitor of the phosphodiesterase subtype 5, which is selective for cGMP
- removes cGMP and thus terminates the action of NO (if protein nitrosylation is neglected)
- Sildenafil was not developed with its now-famous application in mind; instead, the idea was to come up with another vasodilator. Its enhancing effect on penile erection gave rise to the discovery that NO actually is the transmitter that triggers this process.
- **Thus, without NO, no one of us would even be here today!**



http://watcut.uwaterloo.ca/webnotes/Pharmacology/noNosInhibitors_ws.png

Detectce NO

Priame stanovenie NO:



- Gas-phase chemiluminescence assay
- Electron paramagnetic resonance (EPR)
- Electrochemical detection
- cell-permeabilní fluorescenční indikátory (4,5-diaminofluorescein diacetate (DAF-2 DA)

Nepriame stanovenie NO:

- celková koncentrace nitrátů/nitritů (Griessova metoda)
- aplikace NO donorů compounds, NO scavengerů, a guanylyl-cyklásy
- NOS aktivita v buněčných homogenátech měřením enzymatické konverze argininu na citrulin během tvorby NO
- inhibitory NOS (L-NAME)
- aplikace protilátek k isoformám NOS (imunocytochemie, imunoblotting)
- exprese genu pro iNOS

Duo•18

Now records data directly from NOMKII, EVOMX,
ISO2, pH electrodes and Ion Selective Electrodes!




NO Detection by Gas Phase Chemiluminescence

Detection Principle:


NO is purged from an aqueous solution using an inert gas such as Ar or He and transferred to a mixing chamber where it reacts with O₃ under reduced pressure.



The light emitted by excited NO₂ upon returning to the ground state is measured by photon counting (**fmol-pmol**). Not very useful when attempting to quantify NO in physiological fluids such as serum, plasma or urine. Why?



Bioimaging of Nitric Oxide Using Diaminofluoresceine-2 (DAF-2)






Kojima et al., Biol. Pharm. Bull. (1997)

Assay limitations: Possible interference by reducing agents and divalent cations, requires standardized illumination conditions

- A home-made miniature saturated silver/silver chloride reference electrode
- B porphyrinic microsensor working electrode
- C platinum wire counter electrode

ISO-NO Mark II
NO meter (World
Precision
Instruments
(WPI))

DUO 18 two-
channel data-
system (WPI)







RAW 264.7 (1×10^6) (100x)





porphyrinic microsensor ($7 \mu\text{m}$ in
diameter, typical length 0.5-1 mm)


RESULTS


Measurement of NO release from RAW 264.7 cell line using microsensor





BAEC + L-NAME





Parkinson's
Disease

